ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-12-31 was -367.00K shares.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-09-30 was 592.00K shares.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.35M shares, a 26.46% decline from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.83M shares.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 490.00K shares, a 55.56% increase from fiscal 2017.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 315.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-12-31 | 1.35M shares 10-K · filed 2025-04-01 | |
| 2022-12-31 | 1.83M shares 10-K · filed 2024-03-29 | |
| 2018-12-31 | 490.00K shares 10-K · filed 2019-03-26 | |
| 2017-12-31 | -367.00K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-03-26 | 315.00K shares 10-K · filed 2019-03-26 |
| 2017-09-30 | 592.00K shares 10-Q/A · filed 2018-08-20 | |
| 2014-12-31 | 0.00 shares 10-K · filed 2016-03-29 | |
| 2013-12-31 | 25.00K shares 10-K · filed 2016-03-29 | |
| 2012-12-31 | 0.00 shares 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |